Neuromidine, pills 20mg, 50pcs

Pharmacological action

Neuromidin® It has a direct stimulating effect on the conduction of an impulse along nerve fibers, interneuronal and neuromuscular synapses of the central nervous system and peripheral nervous system.

The pharmacological action of Neuromidin® is based on a combination of two mechanisms of action: blockade of potassium channels in the membrane of neurons and muscle cells; reversible inhibition of cholinesterase in synapses.

Neuromidin® enhances the smooth muscle effects of not only acetylcholine, but also epinephrine, serotonin, histamine, and oxytocin.

Neuromidin® has the following pharmacological effects:

– improves and stimulates the conduction of impulses in the nervous system and neuromuscular transmission;

– increases the contractility of smooth muscle organs under the influence of agonists of acetylcholine, adrenaline, serotonin, histamine and oxytocin receptors, with the exception of potassium chloride;

– improves memory, inhibits the progressive course of dementia.

In the preclinical study of Neuromidin® It did not have teratogenic, embryotoxic, mutagenic, carcinogenic and immunotoxic effects, and did not affect the endocrine system.

Indications

• diseases of the peripheral nervous system (mono-and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies);
• diseases of the central nervous system (bulbar paralysis and paresis; recovery period of organic CNS lesions accompanied by motor and / or cognitive disorders);
• intestinal atony (treatment and prevention)(optional for tablets).

Contraindications

• hypersensitivity to any component of the drug;
• epilepsy;
• extrapyramidal hyperkinesis disease;
• angina;
• bradycardia;
• bronchial asthma;
• mechanical obstruction of the intestine or urinary tract;
• vestibular disorders;
• stomach ulcer or duodenal ulcer in the acute stage;
• pregnancy (the drug increases the tone of the uterus);
• lactation;
• children up to age 18 years (there are no systematic data on the application).

With caution:  patients with peptic ulcer of the stomach and duodenum, thyrotoxicosis, diseases of the cardiovascular system, as well as patients with a history of obstructive diseases of the respiratory system or acute respiratory diseases.

Optional for tablets

With caution:  with lactase deficiency, lactose intolerance, lactose/isomaltose malabsorption syndrome, because the drug contains lactose.

Side effects

Caused by the excitation of m-cholinergic receptors: salivation, increased sweating, palpitations, nausea, diarrhea, jaundice, bradycardia, epigastric pain, increased bronchial secretions, bronchospasm, convulsions.

Salivation and bradycardia can be reduced with m-holinoblockers (atropine, etc. ). Increased uterine tone, allergic skin reactions.

Rarely (after higher doses) dizziness, headache, pain behind the sternum, vomiting, general weakness, drowsiness, skin reactions (pruritus, rash) were observed. In these cases, reduce the dose or stop taking the drug for a short time (for 1-2 days).

These side effects are observed in less than 10% of patients.

Interaction

Neuromidine ® enhances the sedative effect in combination with agents that depress the central nervous system.

The effect and side effects are enhanced when combined with other cholinesterase inhibitors and m-cholinomimetic agents. In patients with myasthenia gravis, the risk of developing a cholinergic crisis increases if Neuromidin® is used simultaneously with other cholinergic agents.

The risk of developing bradycardia increases if beta-blockers were used before starting treatment with Neuromidin®.

Neuromidin® can be used in combination with nootropic drugs.

Alcohol increases the side effects of the drug.

Weakens the inhibitory effect on the neuromuscular transmission and conduction of excitation along the peripheral nerves of local anesthetics, aminoglycosides, and potassium chloride.

How to take, course of use and dosage

Inside. The dose and duration of treatment are determined individually, depending on the severity of the disease. Diseases of the peripheral nervous system, myasthenia gravis and myasthenic syndrome: 10-20 mg (0.5-1 tablet) 1-3 times a day. The course of treatment is from one to two months. If necessary, the course of treatment can be repeated several times with a break between courses of 1-2 months. To prevent myasthenic crises in severe neuromuscular conduction disorders,1-2 ml (15-30 mg)is briefly parenterally administered Neuromidin ® 1.5% solution for injection, then treatment is continued with Neuromidin® tablets, the dose can be increased to 20-40 mg (1-2 tablets) 5 times a day. Treatment and prevention of intestinal atony: 20 mg (one tablet) 2-3 times a day for 1-2 weeks. If the next dose was not taken on time, then it is not taken additionally. The maximum daily dose is 200 mg.

Overdose

Symptoms: decreased appetite, bronchospasm, lacrimation, increased sweating, pupil constriction, nystagmus, increased gastrointestinal motility, spontaneous defecation and urination, vomiting, jaundice, bradycardia, intracardiac conduction disorders, arrhythmias, decreased blood pressure, anxiety, anxiety, agitation, fear, ataxia, convulsions, coma, speech disorders, drowsiness, general weakness. Treatment: in case of overdose of tablets — gastric lavage. use of m-cholinolytics, including atropine, cyclodol, metacin, etc. ; symptomatic therapy.

Special instructions

There are no systematic data on the use of Neuromidin® in children.

Alcohol should be excluded for the duration of treatment (increases the side effects of the drug).

Influence on the ability to drive a car or perform work that requires an increased rate of physical and mental reactions.

During treatment, you should refrain from driving a car, as well as engaging in potentially dangerous activities that require increased concentration of attention and speed of psychomotor reactions.

Storage conditions

The drug should be stored in a dry place protected from light at a temperature not exceeding 25°C.

Shelf life

3 years

Active ingredient

Ipidacrine

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For adults as directed by your doctor

Indications

Polyneuropathy, Neuritis